ExonHit and BioMerieux end colon cancer collaboration


The partners say the clinical data did not reach the required level of performance.

ExonHit Therapeutics and BioMerieux will not pursue their colon cancer collaboration after reviewing the clinical data. Both companies will instead focus their efforts on a prostate cancer programme.

Sign up for your free email newsletter

ExonHit's technology was able to produce a robust and reproducible test, however, the final results from the colon cancer programme did not reach the level of performance we were aiming to achieve," said Loic Maurel, president of the management board of ExonHit Therapeutics.